Idarubicin

Summarized by Plex Health
Last Updated: 02 May 2022
high-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation. "high-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation.", by Goel SA, Guo LW, Wang B, Guo S, Roenneburg D, Ananiev GE, Hoffmann FM, Kent KC. pone-0089349-g005: Inhibitory effect of idarubicin on intimal hyperplasia in balloon-injured rat carotid arteries.Following balloon angioplasty, idarubicin was applied locally around the injured arteries. Morphometric analysis was performed on the sections of carotid arteries collected on...

Idarubicin is used in combination radiation treatment to treat severe myeloid leukemia, a type of blood cancer. Idarubicin may be used for functions not listed in this drug overview. Idarubicin can increase your risk of bleeding or infection. Call your medical professional if you have unusual bleeding or bruising, or new signs of infection. Idarubicin might cause harmful effects on your heart, particularly if you have heart issues, if you have obtained certain cancer drugs in the past, or if you are over 60. Idarubicin might cause dangerous effects on your heart. It is not recognized whether idarubicin will hurt unborn baby. Tell your physician if you are pregnant or plan to conceive. Idarubicin is usually offered along with other cancer medicines. Tell your caretakers if you feel any burning, pain, or swelling around the IV needle when idarubicin is infused. Idarubicin can increase your risk of bleeding or infection. If you miss a consultation for your idarubicin injection, call your medical professional for instructions.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.

PubChem - CovalentUnitCount

(Table source)
CIDMolecularFormulaMolecularWeightCanonicalSMILESIsomericSMILESInChIInChIKeyIUPACNameXLogPExactMassMonoisotopicMassTPSAComplexityChargeHBondDonorCountHBondAcceptorCountRotatableBondCountHeavyAtomCountIsotopeAtomCountAtomStereoCountDefinedAtomStereoCountUndefinedAtomStereoCountBondStereoCountDefinedBondStereoCountUndefinedBondStereoCountCovalentUnitCount
42890C26H27NO9497.5CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)OC[[email protected]]1[[email protected]]([[email protected]](C[[email protected]@H](O1)O[[email protected]]2C[[email protected]@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)OInChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1XDXDZDZNSLXDNA-TZNDIEGXSA-N(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione1.9497.16858144497.16858144177912051033606600001
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.

logo

Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.